Last month, researchers from around the globe gathered at the International AIDS Society’s 10th Conference on HIV Science (IAS 2019) in Mexico City to present and discuss the latest advances in HIV research. To help our followers keep up to date on these developments, HIV.gov shared several updates from the conference via Facebook Live. These updates featured Dr. Anthony Fauci and Dr. Carl Dieffenbach of NIH’s National Institute of Allergy and Infectious Diseases (NIAID) who explained some of the research highlights coming out of the conference and put them in context.
For your convenience, we’ve summarized all of our coverage below so you can catch up on any of the posts or video interviews that you missed or share them with your colleagues.
Dr. Fauci Discusses Ending the HIV Epidemic from the 2019 IAS Conference on HIV Science
After delivering two presentations on ending the HIV epidemic at the conference, Dr. Fauci, Director of NIAID, shared highlights of both talks. He observed that we now have the HIV prevention and treatment tools that, if implemented properly and aggressively, could theoretically end the HIV epidemic. Check out the video for his discussion of related key issues and obstacles to be addressed in order to achieve the goal of ending the HIV epidemic.
Watch the full conversation on FacebookExit Disclaimer.
HIV Research Updates from NIH’s Dr. Carl Dieffenbach at the 10th IAS Conference on HIV Science
As the conference opened, Dr. Dieffenbach, who is director of the Division of AIDS at NIAID, gave us a sense of what is new in the HIV prevention landscape, including HIV vaccine research. He also discussed new findings presented at the conference about a potential association between the HIV treatment medication dolutegravir and birth defects in babies born to women who were taking dolutegravir at the time of conception.
Watch the full conversation on FacebookExit Disclaimer.
HIV Prevention Research Updates from the 2019 IAS Conference on HIV Science
On July 24, Dr. Dieffenbach shared several advances in HIV prevention research including news of a new experimental implantable form of HIV pre-exposure prophylaxis (PrEP), additional analysis of a drug combination being considered for daily oral PrEP, and findings from two studies that looked deeper into population characteristics and transmission dynamics to help people adhere to HIV prevention and treatment.
Watch the full conversation on FacebookExit Disclaimer.
HIV Treatment Advances and Other Final HIV Research Updates from the 2019 IAS Conference on HIV Science
As the conference wrapped up, Dr. Dieffenbach discussed advances in HIV treatment options and studies on HIV prevention for women and girls. He also reflected on some key meeting takeaways and looked ahead to anticipated research developments on the horizon.
Watch the full conversation on FacebookExit Disclaimer.
Our thanks to Dr. Fauci, Dr. Dieffenbach, and their colleague Anne Rancourt for bringing us these informative HIV research updates!
To learn more:
- Visit the conference websiteExit Disclaimer to access research abstracts, videos of the presentations, news releases, and more.
You can catch up on and follow our ongoing coverage of HIV-related research using the research topic tag.